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OBJECTIVES The purpose of this study was to compare the treatment effects of septal myectomy with
dual-chamber pacing in patients with hypertrophic obstructive cardiomyopathy (HOCM).
BACKGROUND The optimal treatment for symptomatic patients with drug-refractory HOCM is unknown.
Both dual-chamber pacing and surgical myectomy may result in subjective symptom
improvement. However, no direct comparisons with objective end points have been reported.
METHODS Thirty-nine patients with symptomatic HOCM were analyzed in this concurrent cohort
study. Twenty patients underwent surgical myectomy, and 19 received dual-chamber
pacemakers based on patient preference. These patients had prospective baseline and
follow-up evaluations including physician assessment, echocardiography and standardized
metabolic treadmill exercise testing.
RESULTS Baseline symptom status, left ventricular outflow tract gradients, exercise times and maximal
oxygen consumption peak were similar between the two groups. Left ventricular outflow
gradient was reduced from 76 6 57 to 9 6 17 mm Hg (p 5 0.0001) after myectomy, and
from 77 6 61 to 55 6 39 mm Hg (p 5 0.07) after pacing (p 5 0.02 for comparison with
myectomy). Ninety percent of myectomy patients experienced symptomatic improvement as
compared with 47% in the pacing group. Exercise duration increased significantly from 6.6 6
2.8 to 8.7 6 3.0 min (p 5 0.0003) after myectomy compared with a change from 6.4 6 2.1
to 7.0 6 2.2 min (p 5 NS) in the pacing group. Maximal oxygen consumption increased from
19.4 6 6.4 to 22.2 6 6.5 ml/kg/min after myectomy (p 5 0.004), whereas the pacing group
did not experience any significant change (19.6 6 6.5 vs. 20.1 6 6.5 ml/kg/min, p 5 NS).
CONCLUSIONS Surgical myectomy and dual-chamber pacing improve subjective measures of functional status
in patients with symptomatic HOCM. In this nonrandomized study, myectomy offered
greater reduction in left ventricular outflow tract gradients and larger improvements in
objective measures of patient symptoms and functional status when compared with dual-
chamber pacing. (J Am Coll Cardiol 1999;34:191–6) © 1999 by the American College of
Cardiology
The treatment of patients with hypertrophic obstructive
cardiomyopathy (HOCM) refractory to medical therapy is
controversial. Surgical myectomy, when performed in expe-
rienced centers, has been shown to be safe and efficacious in
relieving the left ventricular outflow obstruction and im-
proving symptoms (1–6). Implantation of a dual-chamber
pacemaker may also provide hemodynamic and symptom-
atic improvement in selected patients (7–10). Although
implantation of a dual-chamber pacing device is less invasive
than septal myectomy, it has been suggested that its results
may not be as beneficial as initially proposed (10–12).
The clinical decision regarding the optimal therapy of
this subset of patients should be based on multiple factors
including age, lifestyle and risk of surgery. Knowledge of the
outcome of these two treatment modalities is required,
including objective measures of functional status. The pur-
pose of this nonrandomized cohort study is to directly
compare the subjective and objective outcomes of these two
treatment modalities, performed at a single center, in
patients with symptomatic HOCM.
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METHODS
Patients. This study is part of an ongoing, prospective
analysis of patients presenting to the Hypertrophic Cardio-
myopathy Clinic at our institution. The patients in this
report were seen by one of two investigators (R.A.N.,
A.J.T.) between May 1993 and August 1997. The diagnosis
of HOCM in all patients was established by the standard
two-dimensional echocardiographic feature of hypertrophy
of the myocardium in the absence of identifiable etiology.
All patients had disproportionate septal hypertrophy, either
diffusely or localized to the basal septum. During systole,
there was projection of the septum into the left ventricular
outflow tract with systolic anterior motion of the mitral
valve in all patients. Patients with concomitant midventricu-
lar obstruction, anomalous insertion of the papillary muscle
or localized apical hypertrophy were excluded from this
report. The maximum left ventricular outflow tract gradient
was determined using standard Doppler echocardiography.
Patients who were considered candidates for therapeutic
modalities to decrease dynamic left ventricular outflow
obstruction were those with 1) a resting left ventricular
outflow tract gradient of .50 mm Hg or 2) a provoked
gradient of .50 mm Hg for those patients with resting
gradients 30 to 50 mm Hg (13–15). The subset of patients
in this study consisted of those with left ventricular outflow
obstruction who were severely symptomatic despite optimal
medical therapy with beta-adrenergic antagonists, calcium
channel inhibitors, or both. The decision to proceed with
septal myectomy or dual-chamber pacing was based on
patient decision after outlining the benefits and risks of each
therapeutic modality. The surgical group represents a subset
of the 89 isolated surgical myectomies (i.e., no bypass grafts
or concomitant valvular surgery) performed between May
1993 and August 1997. Only these 20 patients had the
appropriate preoperative and postoperative exercise testing
and are included in this report. The pacing group consisted
of 19 patients referred between November 1993 and January
1995. The results of a randomized crossover trial of pacing
mode were included in a previous report (10). Patients were
excluded if there was concomitant cardiac disease such as
primary valvular pathology or coronary artery disease.
Initial evaluation. All patients were interviewed and ex-
amined by an experienced cardiologist. Symptomatology
was assessed by the New York Heart Association (NYHA)
classification. After the initial examination, comprehensive
two-dimensional and Doppler echocardiography was per-
formed to assess ventricular morphology, dynamic left
ventricular outflow obstruction (peak instantaneous gradi-
ent), systolic anterior motion of the mitral apparatus and
severity of mitral regurgitation.
Exercise testing. The symptom-limited maximal treadmill
exercise test was performed according to a standard Mayo
protocol with simultaneous respiratory gas analysis. The
exercise protocol consists of an initial stage of 2.5 metabolic
equivalents for the first 2 min with increases by 2 metabolic
equivalents every 2 min. Expired gas analysis was performed
using a Medical Graphics CPX cart. The maximal exercise
oxygen consumption (VO2 peak) was defined as the highest
16-breath average during the test. Standard age, gender and
activity level algorithms were used to predict VO2 peak for
each patient. These are expressed as % predicted 5 100 3
(observed value/predicted value).
Surgery. Standard cardiopulmonary bypass and myocardial
preservation techniques were used. After aortotomy, exci-
sion of the septum was initiated with two parallel longitu-
dinal incisions: one beneath the nadir of the right aortic
cusp and the second beneath the commissure separating the
right and left cusps. The incisions were joined superiorly
and a mass of muscle was excised to the level of the papillary
muscles. Additional myocardium was removed between the
initial excision and the lateral attachment of the anterior
mitral leaflet. The left ventricular outflow tract was in-
spected and palpated for completeness of the resection,
before the closure of the aortotomy.
Pacing protocol. All patients underwent hemodynamic
catheterization to assess the immediate response to dual-
chamber pacing. This protocol has been previously de-
scribed (10). In brief, catheterization of the aorta, left
ventricle (via transseptal technique) and right heart cham-
bers was performed simultaneously with Doppler echocar-
diography. The optimal atrioventricular interval was defined
as that producing the lowest left ventricular outflow tract
gradient without compromise of aortic or left atrial pres-
sures (8,9). By protocol, the tested intervals were 60, 100,
140, 180, 200 and 240 ms. Patients then underwent
placement of dual-chambered permanent pacemakers.
Follow-up. All patients in this study returned to the
Hypertrophic Cardiomyopathy Clinic for follow-up includ-
ing repeat clinical evaluation, echocardiography and meta-
bolic treadmill testing. The mean length of follow-up after
myectomy was 415 days. For patients who underwent the
pacing protocol, patients were prospectively studied after 2
to 3 months of continuous dual-chamber pacing.
Statistics. Data are expressed as mean 6 SD. Repeated
measures analysis of variance was used to test for differences
in continuous variables between the two treatment groups.
New York Heart Association functional classification was
analyzed as a continuous variable as above and as an ordinal
variable using the Wilcoxon rank-sum test. Multivariate
linear regression was used to assess variable independence
Abbreviations and Acronyms
HOCM 5 hypertrophic obstructive cardiomyopathy
NYHA 5 New York Heart Association
VO2 peak 5 maximal oxygen consumption
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with respect to change in exercise variables. Significance was
defined as p , 0.05.
RESULTS
Baseline characteristics. There were 20 patients in the
surgical group (14 men, six women) with a mean age of
42 6 14 years. At the time of the procedure, medications
included beta-adrenergic blocking agents in 16, calcium
channel blocking agents in 9, disopyramide in 4 and
amiodarone in 3 patients. Seven patients were on two or
more of the above agents. Chronic atrial fibrillation was
present in one patient; two others had intermittent atrial
fibrillation. Five patients in the myectomy group had
undergone prior permanent pacemaker implantation for the
treatment of HOCM, but continued to have significant
symptoms and a residual gradient despite the pacemaker.
None of these five patients had experienced subjective
sustained improvement after the pacemaker implantation.
There were 19 patients in the pacing group (10 men, 9
women) with a mean age of 59 6 13 years (p 5 0.0002 for
the difference in age between the groups). The medication
distributions and dosages were similar. One patient in the
pacing group had undergone myectomy 5 years earlier and
had redeveloped symptoms 1 year before presentation.
Baseline assessment. All patients had significant func-
tional limitations in their daily activity. In the surgical
group, there were 5 patients in class II, 14 in class III and 1
in class IV. This is similar to the distribution in the pacing
group (class II 5 2, class III 5 16, class IV 5 1; Table 1,
Fig. 1).
Baseline left ventricular outflow gradient (76 6 57 vs.
77 6 61 mm Hg, p 5 NS), exercise times (6.6 6 2.8 vs.
6.4 6 2.1 min, p 5 NS), % predicted exercise times (54 6
19 vs. 56 6 24%, p 5 NS) and VO2 peak (19.4 6 6.4 vs.
19.6 6 6.5 ml/kg/min, p 5 NS) were similar between the
surgical and pacing groups, respectively.
Posttreatment assessment. There were no deaths in either
group during the follow-up period. Left ventricular outflow
gradient was reduced from 76 6 57 mm Hg to 9 6
17 mm Hg (p 5 0.0001, comparison of pretreatment with
posttreatment) in the surgical group as compared with a
reduction from 77 6 61 mm Hg to 55 6 39 mm Hg (p 5
0.07) in the pacing group (Fig. 2). The change in gradient
after therapy was significantly different between the two
groups (p 5 0.03). Eighteen (90%) of the surgical patients
had residual gradients of less than 20 mm Hg, whereas 5
(26%) of the pacing patients had posttreatment gradients of
less than 20 mm Hg.
All of the myectomy patients were in functional class I–II
at the time of follow-up. Nearly half (n 5 9) of the pacing
patients remained in class III–IV, with 10 patients experi-
encing no symptomatic improvement. New York Heart
Table 1. Pre- and Post-treatment Data for Patients with Drug Refractory HOCM
Myectomy (n 5 20) DDD Pacing (n 5 19)
Pre Post Change Pre Post Change
Age (yr) 42 6 14 59 6 13*
LVOT gradient (mm Hg) 76 6 57 9 6 17† 63 6 59 77 6 61 55 6 39*† 22 6 50*
NYHA class 2.8 6 0.6 1.3 6 0.5† 1.5 6 0.9 2.9 6 0.4 2.4 6 0.8*† 0.5 6 0.6*
Exercise time (min) 6.6 6 2.8 8.7 6 3.0† 2.1 6 2.1 6.4 6 2.1 7.0 6 2.2* 0.8 6 1.8*
% predicted 54 6 19 74 6 24† 20 6 24 56 6 24 63 6 16† 7 6 13*
VO2 peak (ml/kg/min) 19.4 6 6.5 22.2 6 6.5† 2.9 6 3.9 19.6 6 6.5 20.1 6 6.5 0.6 6 2.9*
% predicted 52 6 15 61 6 14† 9 6 12 70 6 15* 71 6 14* 1 6 12*
*p , 0.05 for comparison between groups.
†p , 0.05 for comparison within groups.
DDD 5 dual-chamber; LVOT 5 left ventricular outflow tract; NYHA 5 New York Heart Association; VO2 peak 5 peak oxygen consumption.
Figure 1. Change in New York Heart Association (NYHA) classification from baseline to follow-up for patients undergoing surgical
septal myectomy or dual-chamber (DDD) pacing.
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Association functional class improved from 2.8 6 0.5 to
1.3 6 0.5 (p , 0.0001) after myectomy and from 2.9 6 0.4
to 2.4 6 0.7 (p 5 0.002) after dual-chamber pacing. The
improvement in functional class after therapy was signifi-
cantly better in the myectomy group (p 5 0.0006). The
stated p values are consistent when tested as continuous or
ordinal data.
Treadmill exercise duration improved by 32% from 6.6 6
2.8 to 8.7 6 3.0 min (p 5 0.0003) in the myectomy group
compared with an improvement of 9% from 6.4 6 2.1 to
7.0 6 2.2 min (p 5 NS) in the pacing group (Fig. 3). The
difference in improvement between the two treatment
groups was statistically significant (p 5 0.05). The postmy-
ectomy VO2 peak increased from 19.4 6 6.5 to 22.2 6 6.5
ml/kg/min (p , 0.004), whereas the pacing group had an
insignificant change from 19.6 6 6.5 to 20.1 6 6.5
ml/kg/min. Improvement in VO2 peak was greater in the
surgical group compared with the pacing group (p 5 0.04,
Fig. 4). On the basis of predicted percentage values for VO2
peak, the myectomy patients had a more significant baseline
impairment (52 6 15% vs. 70 6 15%, p 5 0.0005), and
showed more improvement posttreatment (9 6 12% vs. 1 6
12%, p 5 0.04). There were no differences before or after
treatment with respect to the peak exercise respiratory
exchange ratio or ventilatory anaerobic threshold between
the two groups.
Subset analysis. There were nine patients in the pacing
group who experienced improvement in symptoms. In these
9 patients, the exercise time increased from 7.3 to 7.7 min
and peak VO2 increased from 22.2 to 23.2 ml/kg/min. The
magnitude of the increase in objective functional capacity in
these 9 patients was less than observed in the myectomy
group (increase in exercise time 0.9 6 1.2 vs. 2.1 6 2.1 min,
increase in peak VO2 1.0 6 3.0 vs. 2.9 6 3.9 ml/kg/min).
There were only four patients in our pacing group who
increased exercise time by .2 min. These patients could not
be distinguished from the remainder of the pacing patients
using pretreatment data.
DISCUSSION
The pathophysiology producing symptoms in HOCM is
complex and includes left ventricular outflow obstruction,
diastolic dysfunction, mitral regurgitation and arrhythmias
(16–20). The goal of therapy has been directed against the
outflow obstruction. Reduction of the left ventricular out-
flow obstruction may subsequently influence the diastolic
filling characteristics of the left ventricle through changes in
loading conditions and decreasing severity of mitral regur-
gitation, if the mitral regurgitation is secondary to distortion
of the mitral apparatus from systolic anterior motion.
Despite initial concerns regarding the efficacy of decreasing
(or eliminating) the outflow obstruction by surgical means
(21–23), surgical myectomy has been shown to produce
excellent relief in symptomatic patients with HOCM (1–
4,24–26).
Implantation of a dual-chamber pacemaker has been
shown to decrease the severity of left ventricular outflow
obstruction and improve symptoms (7,8). It is a less invasive
Figure 2. Change in Doppler-derived resting left ventricular
outflow tract (LVOT) gradient from baseline to follow-up assess-
ment. Both groups (surgical myectomy, left; dual-chamber pacing,
right) show significant reductions in resting gradient (p , 0.05).
Figure 3. Effects of treatment modalities on exercise duration. The
surgical myectomy patients show a significant increase (*p , 0.05),
whereas the pacing patients do not. Open bars 5 pretreatment;
solid bars 5 posttreatment.
Figure 4. Effects of treatment modalities on peak oxygen con-
sumption (VO2) in patients treated for symptomatic hypertrophic
obstructive cardiomyopathy (*p , 0.05). Open bars 5 pretreat-
ment; solid bars 5 posttreatment.
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technique that is more widely available to the cardiology
community. The initial enthusiasm for permanent pacing as
a treatment panacea has been tempered by more modest
results in recent studies (10,11).
In clinical decision making, it is necessary to have an
objective comparison of the results of the two therapeutic
modalities. Controlled randomized trials are the standard by
which outcomes may be compared but may not be possible
in uncommon diseases such as HOCM. Thus, the results of
prospectively gathered data in cohort series must be made
available.
Effects on left ventricular outflow gradient. In the
present study, both surgical myectomy and dual-chamber
pacing resulted in overall reductions in left ventricular
outflow tract gradient, with a greater reduction in gradient
after myectomy. This is not unexpected, because the ana-
tomic dimensions of the outflow tract are altered by the
operation. Improvements in the diastolic filling properties of
the left ventricle may be best achieved by near abolition of
the outflow obstruction with consequent changes in con-
traction load on the left ventricle (17). This near abolition of
the gradient was achieved in 90% of patients undergoing
myectomy versus only 26% of patients in the pacing group.
Our results are similar to previously reported hemodynamic
results (1,2,27,28).
Subjective status. A higher percentage of patients experi-
enced subjective symptomatic improvement after myectomy
as compared with pacing (90% vs. 47%). There are many
limitations to the subjective NYHA classification, but it
provides a semiquantitative assessment of a patient’s life-
style. A possible “placebo effect” must always be taken into
consideration in the subjective evaluation of any therapeutic
modality (7,9,10). Nonetheless, symptom improvement is
the goal of therapy in these patients. In this study, myec-
tomy resulted in 100% of patients in class I–II versus 53% in
the pacing group. The accuracy of the NYHA class is
reflected in the postmyectomy patients: class I patients
exercised 8.9 min vs. 8.1 min for the class II patients.
Likewise, the VO2 peak was nearly 24 ml/kg/min in class I
patients versus 19.9 ml/kg/min in class II patients.
Effects on objective exercise parameters. The comparison
of the effect of treatment on the objective measures of
exercise performance was interesting. Exercise duration
showed more overall improvement in the surgical group as
compared with the pacing group. Maximal oxygen con-
sumption, which is a more specific indicator of cardiac
performance than exercise time, and % predicted VO2 peak
were measured. The surgical group experienced significantly
better improvements in these measures of oxygen consump-
tion than the pacing group. The postsurgical improvements
in exercise duration and VO2 peak are similar to published
results from the National Institutes of Health (1).
Two randomized crossover trials of dual-chamber pacing
examined objective measures of exercise tolerance (28,29).
Although the overall improvements in these objective pa-
rameters were modest, they retrospectively identified subsets
of patients who achieved significant improvements in exer-
cise time and VO2 peak. In our own pacing group there
were only four patients with improvements in exercise time
comparable to the surgical group. This small group of
patients could not be identified on the basis of any preim-
plantation parameter.
Study limitations. There are multiple limitations of this
nonrandomized cohort analysis of a small number of pa-
tients. This study was not “designed” as a prospective
investigation but rather, was a retrospective analysis
prompted by the controversies with respect to treatment
modalities in these patients. This introduces the inherent
deficiencies and potential bias of any retrospective analysis.
Patients were assigned to treatment based on patient pref-
erence, and thus may not be comparable. There were
significant differences in baseline age; the myectomy pa-
tients were younger than the pacing patients. However, the
baseline symptomatic status, the baseline exercise duration
and the baseline VO2 peak were similar between the two
groups. There was also no difference in the severity of the
left ventricular outflow tract obstruction between the pacing
and surgical groups.
The two groups were not true concurrent cohorts, as the
entry of patients into the pacing group ended before that of
the surgical group. Patients who underwent dual-chamber
pacing from 1995 to 1997 are part of a multicenter random-
ized trial, which has shown similar results to the initial
pacing study (29).
This surgical group represents only a subset of the total
myectomy population during the study period (n 5 89),
thus the applicability of the results to all patients undergo-
ing surgical myectomy was not evaluated. However, many
patients undergoing myectomy were not included in this
study because the patients were felt to be too sick for
preoperative exercise testing. Of these patients not included
in this report who returned to the Hypertrophic Cardiomy-
opathy Clinic after surgical myectomy, 95% were NYHA
class I–II. Thus, the inclusion of these patients would have
strengthened the conclusions of the study.
The current data do not include the placebo effect on
symptomatic improvement or the training effect on objec-
tive measures of exercise tolerance. Both of these factors
may play significant roles in the analysis of the effect of
intervention, as has been recently demonstrated in random-
ized crossover trials. The long duration of sustained im-
provement in the surgical group (mean follow-up 415 days)
mitigates against a placebo effect. There was no difference in
comparisons between the groups or comparing pretreatment
and posttreatment data within groups in the respiratory
exchange ratio, which measures the degree of effort or in
anaerobic threshold that is subject to “training effects.”
Follow-up was longer in the surgical group as compared
with the pacing group. However, past studies have not
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shown further symptomatic or hemodynamic improvement
beyond the initial three months of dual-chamber pacing
(28,30).
Implications. At the present time, there is not a single
therapy that should be applied to all patients with severely
symptomatic HOCM unresponsive to medical manage-
ment. There are benefits and drawbacks to both surgical
myectomy and dual-chamber pacing. Septal myectomy re-
quires specialized tertiary referral centers and is more
complex than implantation of a permanent pacemaker.
However, surgical treatment of symptomatic HOCM re-
sults in greater improvements in outflow tract gradient
reduction, NYHA symptom class, exercise time and VO2
peak compared with dual-chamber pacing.
There may, however, be a subset of patients who derive
enough benefit from pacing to achieve a satisfactory way of
life, thus avoiding or delaying the need for surgery. There
are some patients who may wish to first undergo the less
invasive route of pacemaker implantation, with the option
of surgical myectomy later if there is no improvement. In
addition, other therapeutic modalities have emerged for
treatment of these patients, such as catheter-based septal
ablation (31,32). Further investigation is required to be able
to identify responders and compare results between the
available treatments. These are the focus of ongoing ran-
domized trials. Ultimately, the decision as to the best
therapy must be individualized to each patient depending on
age, anatomy, hemodynamics, way of life and risks of therapy.
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